A Phase II, Multicentre, Randomised, Double-Blind, Parallel Group, Placebo Controlled Study to Evaluate Safety, Tolerability and Clinical Efficacy of MT 1303 in Subjects with Moderate to Severe Active Crohn*s Disease
- Conditions
- Crohns disease10017969
- Registration Number
- NL-OMON44387
- Lead Sponsor
- Mitsubishi Tanabe Pharma Europe Ltd (MTPE)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 4
1. Able to provide written informed consent and to comply with the requirements of the Protocol;2. Male or female subjects aged between 18 and 65 years (inclusive). For subjects of reproductive potential, two methods of contraception must be used throughout the study and for 12 weeks after cessation of study medication. At least one of the methods of contraception must be a barrier method. ;3. Diagnosis of CD (involving small intestine and/or colon), confirmed at the time by endoscopy and histology at least 3 months prior to Visit 1 (Screening);4. Previous use of corticosteroids or immunosuppressants (such as azathioprine [AZA]/ 6-mercaptopurine [6-MP] or methotrexate [MTX]) or anti-TNF-alpha agents (such as infliximab, adalimumab or certolizumab pegol) for the treatment of CD;5. Moderate to severe active CD defined by a CDAI score of >=220 to <=450 points at Visit 1 ;6. C-reactive protein (CRP) >=5 mg per litre (/L) and/or faecal calprotectin >=250 µg/g;7. A negative stool test result for Clostridium difficile (C. difficile) toxin at Visit 1 ;8. Negative results for both QuantiFERON-TB Gold (or T-SPOT) test and chest x-ray (i.e., no evidence of tuberculosis [TB]) at Visit 1;For detailed information, please refer to the Protocol.
1. Diagnosis of ulcerative colitis, indeterminate colitis, pseudomembranous colitis or coeliac disease ;2. Enterocutaneous, abdominal or pelvic active fistulae, abscesses or fistulae likely to require surgery during the study;3. Gastrointestinal (GI) surgery (including appendectomy) within 12 weeks prior to Visit 2 (Baseline) or has surgery planned or deemed likely to require surgery for CD during the study;4. History or evidence of ileostomy, colostomy, rectal pouch, significant stenosis or extensive resection in GI tract that could impair the drug absorption or interfere with the objectives of the study, as judged by the Investigator ;5. History or evidence of unresected adenomatous colonic polyps or colonic mucosal dysplasia;6. Chronic use of opioid for chronic pain which, in the opinion of the Investigator, would influence the subject reported CDAI parameters. ;7. Use of concomitant medications as described in the protocol. ;8. Presence or history of clinically significant disease (except CD) that could interfere with the objectives of the study or the safety of the subject, as judged by the Investigator ;9. Body weight <=35 kg at Visit 1;10. Presence or history of any of cardiovascular diseases as decsribed in the protocol.;11. Need for, or likely need for treatment with Class I or Class III anti-arrhythmic drugs, or with beta-blockers or heart-rate-lowering calcium-channel blockers, or with any other drugs which can reduce the heart rate ;12. Known high risk for QT/QTc prolongation such as a family history of long QT syndrome or sudden death;13. History or known presence of cerebrovascular diseases ;14. Presence or history (within 5 years prior to initial screening) of malignancy, except for successfully treated basal cell and in situ squamous cell carcinomas of the skin;15. Known history of recurrent or chronic infection such as TB, hepatitis B, hepatitis C or human immunodeficiency virus (HIV);16. Receipt of live vaccine within 4 weeks prior to Visit 2;17. Diagnosis of diabetes mellitus (Type I or II);18. Presence or prior history of macular oedema, uveitis or evolutive retinopathy, or any other condition that could increase the risk of macular oedema in the opinion of the Investigator;19. History of substance abuse (drug or alcohol) or any other factor that limits the subject*s ability to cooperate with the study procedures.;20. Known history of allergy, hypersensitivity or any serious reaction to any component of the study medication ;21. Previous treatment with any investigational agent within 12 weeks prior to Visit 1 OR five half-lives of the investigational product, whichever is the longer.;22. WBC count <3,500/µL at Visit 1;23. Lymphocyte count <800/µL at Visit 1;24. LFT (aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) >=2 x ULN at Visit 1;25. HbA1c >6.5% at Visit 1;26. Negative or indeterminate results for antibodies (IgG) to Varicella Zoster virus (VZV) at Visit 1;27. [For female subjects only] A positive pregnancy test at Visit 1 (serum beta-human chorionic gonadotropin [hCG] level or urine dipstick) or Visit 2 (urine dipstick);28. Low heart rate (<50 beats per minute [bpm]) in 12-lead ECG at Visit 1 or Visit 2 (pre-dose);29. QTcF interval >=450 milliseconds (msec) in 12-lead ECG at Visit 1 or Visit 2 (pre-dose);30. Clinically significant abnormal findings in 12-lead ECG (at Visit 1 or Visit 2 [pre-dose]) and/or in Holter ECG (at Visit 1) that the Investigator considers may jeopardise
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Primary Efficacy Endpoint:<br /><br><br /><br>* The proportion of subjects who achieve a 100-point decrease from Baseline in<br /><br>CDAI score (i.e., CDAI 100) at Visit 6 (Week 12)</p><br>
- Secondary Outcome Measures
Name Time Method <p>Secondary Endpoints:<br /><br><br /><br>Efficacy<br /><br>* Proportion of subjects who achieve a 70-point decrease from Baseline in CDAI<br /><br>score (i.e., CDAI 70) at Protocol-scheduled visits.<br /><br>* Proportion of subjects who achieve a 100-point decrease from Baseline in CDAI<br /><br>score (i.e., CDAI 100) at other Protocol-scheduled visits.<br /><br>* Proportion of subjects who achieve clinical remission (i.e., CDAI score of<br /><br><150) at Protocol-scheduled visits.<br /><br>* CDAI score and change from Baseline in CDAI score at Protocol-scheduled<br /><br>visits.<br /><br><br /><br>Pharmacodynamics<br /><br>* Lymphocyte count and lymphocyte subsets, their change from Baseline, and<br /><br>percentage of Baseline at Protocol-scheduled visits.<br /><br>Pharmacokinetics<br /><br>* PK concentration of MT-1303 and its active metabolite MT-1303-P at<br /><br>Protocol-scheduled visits.</p><br>